February 21, 2019 07:10 AM ESTUpdated 09:23 AM
Deals

Mer­ck­'s Roger Perl­mut­ter pays $300M to scoop up a bat­tered Im­mune De­sign for its I/O work

John Carroll

Editor & Founder

Just months af­ter Im­mune De­sign trig­gered an ex­o­dus of in­vestors with news of a Phase II set­back on its lead­ing im­muno-on­col­o­gy work, Mer­ck has stepped up to buy the com­pa­ny and plug it in­to its im­munol­o­gy group.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times